Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial

Neurology

Volumn 54, Issue 2, 2000, Pages 295-301

  Henderson, Victor W ^a   Paganini Hill, A ^a   Miller, B L ^b   Elble, R J ^f   Reyes, P F ^c   Shoupe, D ^a   McCleary, C A ^a   Klein, R A ^d   Hake, A M ^e   Farlow, M R ^e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d Wyeth Ayerst Research   (United States)

^e INDIANA UNIVERSITY   (United States)

^f NONE

Author keywords

AD; Clinical trial; Cognition; Estrogen; Mood Women

Indexed keywords

CONJUGATED ESTROGEN; PLACEBO;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESTROGEN THERAPY; FEMALE; HUMAN; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0034711656     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.54.2.295     Document Type: Article

References (45)

1. Evans DA, Scherr PA, Cook NR, et al. Estimated prevalence of Alzheimer's disease in the United States. Milbank Quart 1990;68:267-289.
2. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337-1342.
3. Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter JG. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and non-demented control subjects. Arch Neurol 1994;51:896-900.
4. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer's disease. Arch Intern Med 1996; 156:2213-2217.
5. Tang M-X, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-432.
6. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 1997;48:1517-1521.
7. Baldereschi M, Di Carlo A, Lepore V, et al. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology 1998;50:996-1002.
8. Waring SC, Rocca WA, Petersen RC, O'Brien PC, Tangalos EG, Kokmen E. Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology 1999; 52:965-970.
9. Henderson VW, Watt L, Buckwalter JG. Cognitive skills associated with estrogen replacement in women with Alzheimer's disease. Psychoneuroendocrinology 1996;21:421-430.
10. Doraiswamy PM, Bieber F, Kaiser L, Krishnan KR, Reuning-Scherer J, Gulanski B. The Alzheimer's disease assessment scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology 1997;48:1511-1517.
11. Henderson VW. Estrogen replacement therapy for the prevention and treatment of Alzheimer's disease. CNS Drugs 1997;8: 343-351.
12. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994.
13. McKhann G, Drachman D, Folstein MF, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
14. Sands R, Studd J. Exogenous androgens in postmenopausal women. Am J Med 1995;98(suppl 1A):76S-79S.
15. Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 1996;46: 1580-1584.
16. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N. Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports. Dementia 1995;6:99-107.
17. Troy SM, Hicks DR, Parker VD, Jusko WJ, Rofsky HE, Porter RJ. Differences in pharmacokinetics and comparative bioavailability between Premarin and Estratab in healthy post-menopausal women. Curr Ther Res 1994;55:359-372.
18. Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen preparations. Am J Obstet Gynecol 1982;144:511-518.
19. White SJ, Freedman LS. Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer 1978;37: 849-857.
20. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
21. Kramer-Ginsberg E, Mohs RC, Aryan M, et al. Clinical predictors of course for Alzheimer's patients in a longitudinal study: a preliminary report. Psychopharmacol Bull 1988;24:458-462.
22. Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390-396.
23. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Study - Global Impression of Change. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S22-S32.
24. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
25. Montgomery SA, Asberg MA. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
26. Nitcher RL. Collateral source Geriatric Depression Scale. Am J Geriatr Psychiatry 1993;1:143-152.
27. Lezak MD. Neuropsychological assessment. 3rd ed. New York: Oxford University Press, 1995.
28. Shughrue PJ, Lane MV, Merchenthaler I. Comparative distribution of estrogen receptor-α and -β mRNA in the rat central nervous system. J Comp Neurol 1997;388:507-525.
29. Wong M, Thompson TL, Moss RL. Nongenomic actions of estrogen in the brain: physiological significance and cellular mechanisms. Crit Rev Neurobiol 1996;10:189-203.
30. Henderson VW. Estrogen, cognition, and a woman's risk of Alzheimer's disease. Am J Med 1997;103(suppl 3A):11-18.
31. Xu H, Gouras GK, Greenfield JP, et al. Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides. Nat Med 1998;4:447-451.
32. Stone DJ, Rozovsky I, Morgan TE, Anderson CP, Finch CE. Increased synaptic spouting in response to estrogen via an apolipoprotein E dependent mechanism: implications for Alzheimer's disease. J Neurosci 1998;18:3180-3185.
33. L expression and β-amyloid-induced apoptosis: relevance to Alzheimer's disease. J Neurochem 1999;72:1552-1563.
34. Honjo H, Ogino Y, Tanaka K, et al. An effect of conjugated estrogen to cognitive impairment in women with senile dementia - Alzheimer's type: a placebo-controlled double blind study. J Jpn Menopause Soc 1993;1:167-171.
35. Fillit H. Estrogens in the pathogenesis and treatment of Alzheimer's disease in postmenopausal women. Ann NY Acad Sci 1994;743:233-238.
36. Asthana S, Craft S, Baker LD, et al. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology 1999;24:657-677.
37. Birge SJ. The role of estrogen in the treatment of Alzheimer's disease. Neurology 1997;48(suppl 7):S36-S41.
38. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Garcon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991.
39. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-145.
40. Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999;318:633-640.
41. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992;17:485-495.
42. Sherwin BB, Tulandi T. "Add-back" estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. J Clin Endocrinol Metab 1996;81:2545-2549.
43. Schneider LS, Farlow MR, Pogoda JM, Poirier J. Interaction of estrogen replacement therapy and apolipoprotein genotype status on response to cholinesterase inhibitor therapy in Alzheimer's disease. In: Iqbal K, Binblad B, Nishimura T, Takeda M, Wisniewski HM, eds. Alzheimer's disease: biology, diagnosis and therapeutics. New York: John Wiley & Sons, 1997: 657-661.
44. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
45. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-488.